Evercore ISI reiterates Netflix (NFLX.US) "Outperform" rating, bullish on live sports and short-form video as hit-driving engines.
Evercore ISI raised its price target on streaming platform Netflix (NFLX.US) from $100 to $110 and reiterated its "Outperform" rating.
Evercore ISI raised its price target on streaming platform Netflix (NFLX.US) from $100 to $110 and reiterated an "Outperform" rating, citing improving trends in its U.S. and Japan surveys and opportunities from live events and short-form video content.
The new price target implies roughly 42% upside from the stock's latest closing price.
Analyst Kutgun Maral said Netflix's penetration rate in the U.S. reached a multi-year high of 63%, while in Japan it hit a record 22%. Churn intent improved in both markets, but user satisfaction in the U.S. market remains a concern.
The brokerage highlighted live events as a potential subscriber growth catalyst. In Japan, 45% of surveyed new subscribers said they signed up through Netflix's World Baseball Classic promotional campaign, while the share of users who watched live events rose from 42% in March to 60% in September.
Evercore also mentioned Netflix Clips its short-form video feed with 46% of Japanese respondents and 38% of U.S. respondents saying they had browsed the feature.
The analysts said live events and short-form video content help drive engagement and retention, while the ad-supported tier continues to attract new and returning subscribers.
Evercore views Netflix as a sustainable 20% EPS grower and said its catalyst path is more likely to materialize in 2027 rather than 2026.
Related Articles

General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.

EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.

Shanghai Shen Lian Biomedical Corporation (688098.SH): Phase II clinical trial of UB-221 for the treatment of chronic spontaneous urticaria meets primary endpoint

RECOMMEND





